Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT06573593
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    In the real-world settings, patients with AA treated with tofacitinib.
  • Baricitinib — DRUG
    In the real-world settings, patients with AA treated with Baricitinib.
  • Ruxolitinib — DRUG
    In the real-world settings, patients with AA treated with Ruxolitinib.
  • Upadacitinib — DRUG
    In the real-world settings, patients with AA treated with Upadacitinib.
  • Abrocitinib — DRUG
    In the real-world settings, patients with AA treated with Abrocitinib.
  • Ritlecitinib — DRUG
    In the real-world settings, patients with AA treated with Ritlecitinib.

Study Details

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Key Dates

Start date
Jul 29, 2024
Status verified
Jul 2024
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Tofacitinib treated group
    In the real-world settings, patients with AA treated with tofacitinib.
  • Arm: Baritinib treated group
    In the real-world settings, patients with AA treated with baritinib.
  • Arm: Ruxolitinib treated group
    In the real-world settings, patients with AA treated with ruxolitinib
  • Arm: Upadacitinib treated group
    In the real-world settings, patients with AA treated with upadacitinib.
  • Arm: Abrocitinib treated group
    In the real-world settings, patients with AA treated with abhicitinib.
  • Arm: Ritlecitinib treated group
    In the real-world settings, patients with AA treated with ritlecitinib.

Primary Outcome Measure

Mean SALT [ Time Frame: at week 24 ]

Central Contacts

Related Studies